Efgartigimod for treating antibody-positive generalised myasthenia gravis
Technology appraisal guidance
Reference number: TA1069
Published:
Following the committee meeting on 9 May 2024, this appraisal will be paused while further information is provided by the company. An update is expected in June 2024.